Enovis Corporation (ENOV)
NYSE:ENOV
Want to see ENOV full AI Analyst Report?
ENOV Stock Chart & Stats
$26.32
$0.83(1.85%)
At close: 4:00 PM EST
$26.32
$0.83(1.85%)
Day’s Range― - ―
52-Week Range$20.82 - $36.82
Previous CloseN/A
Volume391.51K
Average Volume (3M)1.11M
Market Cap
$1.37B
Enterprise Value$2.68B
Total Cash (Recent Filing)$33.13M
Total Debt (Recent Filing)$1.41B
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Jul 30, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.02
Shares Outstanding57,562,603
10 Day Avg. Volume1,057,080
30 Day Avg. Volume1,114,582
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue1.18
Enterprise Value/Gross Profit2.07
Enterprise Value/Ebitda-13.92
Forecast
1Y Price Target
$42.33Price Target Upside60.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.65
Revenue Forecast (FY)$2.35B
Bulls Say, Bears Say
Bulls Say
Recon Segment Leadership & Product InnovationEnovis’s Recon business demonstrates durable competitive advantage: new systems (Nebula, ARG) and Arvis instrument sets are converting share in hips, knees and shoulders and accelerating ASC adoption. Persistent product-led share gains support long-term procedure penetration and higher-margin sales.
High And Expanding Gross MarginsSustained ~62% gross margins, driven by favorable mix, productivity and synergies, provide structural margin resilience. Higher gross margin cushions SG&A/R&D investments and supports durability of adjusted profitability as top-line recovery and operating leverage continue.
Improving Cash Generation And Healthier LeverageOperating and free cash flow have meaningfully improved and management targets sustained >25% conversion, while leverage has declined versus 2024–2025 levels. Stronger cash conversion and lower leverage improve financial flexibility for R&D, M&A, and capital allocation over the medium term.
Bears Say
Large Operating And Net LossesDespite top-line growth, the income statement shows steep operating and net losses, driving negative returns on equity. Persistent deep losses risk capital depletion, constrain reinvestment capacity, and necessitate sustained margin recovery to restore long-term profitability and shareholder returns.
International Volatility And Regional DisruptionOngoing geopolitical and local market disruptions (strikes, regional volatility) create recurring revenue unpredictability and operational friction. Monthly Middle East exposures and unstable international volumes can erode forecast accuracy and require persistent supply‑chain and commercial mitigation over multiple quarters.
Reduced Non-GAAP Comparability After SEC GuidanceThe SEC-driven change to adjusted EBITDA (no longer excluding inventory step-up) reduces historical non-GAAP comparability and complicates trend analysis. This alters key profitability metrics investors use to assess operating performance and may lengthen the time to rebuild consensus on sustainable margins.
Enovis News
ENOV FAQ
What was Enovis Corporation’s price range in the past 12 months?
Enovis Corporation lowest stock price was $20.82 and its highest was $36.82 in the past 12 months.
What is Enovis Corporation’s market cap?
Enovis Corporation’s market cap is $1.37B.
When is Enovis Corporation’s upcoming earnings report date?
Enovis Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 52 days.
How were Enovis Corporation’s earnings last quarter?
Enovis Corporation released its earnings results on May 07, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.812 by $0.078.
Is Enovis Corporation overvalued?
According to Wall Street analysts Enovis Corporation’s price is currently Undervalued.
Does Enovis Corporation pay dividends?
Enovis Corporation does not currently pay dividends.
What is Enovis Corporation’s EPS estimate?
Enovis Corporation’s EPS estimate is 0.85.
How many shares outstanding does Enovis Corporation have?
Enovis Corporation has 57,562,603 shares outstanding.
What happened to Enovis Corporation’s price movement after its last earnings report?
Enovis Corporation reported an EPS of $0.89 in its last earnings report, beating expectations of $0.812. Following the earnings report the stock price went up 9.658%.
Which hedge fund is a major shareholder of Enovis Corporation?
Currently, no hedge funds are holding shares in ENOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (60.84% Upside)
$42.33 (60.84% Upside)
Blogger Sentiment
Bullish
ENOV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 563.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $142.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.74%
12-Months-Change
Fundamentals
Return on Equity
-60.13%
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
ENOV Company Deck
ENOV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all ENOV earnings summariesENOV Stock 12 Month Forecast
Average Price Target
$42.33
▲(60.84% Upside)
Technical Analysis
Ownership Overview
2.08% Insiders
34.85% Mutual Funds
31.93% Other Institutional Investors
0.29% Public Companies and
Individual Investors